Suppr超能文献

为发展中国家的研究参与者规划试验后获得抗逆转录病毒治疗的途径。

Planning for posttrial access to antiretroviral treatment for research participants in developing countries.

作者信息

Shah Seema, Elmer Stacey, Grady Christine

机构信息

Department of Bioethics, Clinical Center, and the Henry Jackson Foundation Liaison Office, Division of AIDS, National Institutes of Health, Bethesda, MD, USA.

出版信息

Am J Public Health. 2009 Sep;99(9):1556-62. doi: 10.2105/AJPH.2008.157982. Epub 2009 Jul 16.

Abstract

Despite recognition of the importance of posttrial access to antiretroviral therapy (ART), the implementation process has not been studied. We examined whether the National Institutes of Health (NIH) guidance document was being implemented in NIH-funded ART trials conducted in developing countries between July 2005 and June 2007. All of the 18 studies we identified had posttrial access plans for trial participants. More than 70% had specific mechanisms for posttrial access, but none guaranteed long-term sponsor funding after the trials. The plans reflected variation in local contexts and the uncertainty of predicting local conditions in the long term. The strength of the NIH guidance document may be that it encourages investigators to formulate plans in advance and to work with other stakeholders to provide access to ART.

摘要

尽管认识到试验后获得抗逆转录病毒疗法(ART)的重要性,但尚未对实施过程进行研究。我们调查了2005年7月至2007年6月期间在发展中国家开展的由美国国立卫生研究院(NIH)资助的ART试验中,NIH指导文件是否得到了实施。我们确定的18项研究均为试验参与者制定了试验后获取计划。超过70%的研究有试验后获取的具体机制,但没有一项能保证试验结束后有长期的资助方资金。这些计划反映了当地情况的差异以及长期预测当地状况的不确定性。NIH指导文件的优势可能在于它鼓励研究人员提前制定计划,并与其他利益相关者合作以提供ART获取途径。

相似文献

1
Planning for posttrial access to antiretroviral treatment for research participants in developing countries.
Am J Public Health. 2009 Sep;99(9):1556-62. doi: 10.2105/AJPH.2008.157982. Epub 2009 Jul 16.
3
The obligation to provide antiretroviral treatment in HIV prevention trials.
AIDS. 2007 Jun 19;21(10):1229-31. doi: 10.1097/QAD.0b013e3281338371.
4
Access to antiretroviral treatment in developing countries: Which financing strategies are possible?
Rev Epidemiol Sante Publique. 2010 Jun;58(3):171-9. doi: 10.1016/j.respe.2010.03.002. Epub 2010 Apr 28.
5
Community perspectives on care options for HIV prevention trial participants.
AIDS Care. 2007 Apr;19(4):554-60. doi: 10.1080/09540120601035284.
6
Monitoring of HIV treatment in seven countries in the WHO Region of the Americas.
Bull World Health Organ. 2015 Aug 1;93(8):529-39. doi: 10.2471/BLT.14.147447. Epub 2015 May 27.
8
Financing equitable access to antiretroviral treatment in South Africa.
BMC Health Serv Res. 2010 Jul 2;10 Suppl 1(Suppl 1):S2. doi: 10.1186/1472-6963-10-S1-S2.
9
Regulatory impediments jeopardizing the conduct of clinical trials in Europe funded by the National Institutes of Health.
Clin Trials. 2010 Dec;7(6):705-18. doi: 10.1177/1740774510376547. Epub 2010 Aug 20.

引用本文的文献

1
Post-trial responsibilities in pragmatic clinical trials: Fulfilling the promise of research to drive real-world change.
Learn Health Syst. 2024 Mar 6;8(3):e10413. doi: 10.1002/lrh2.10413. eCollection 2024 Jul.
2
An Ethical Imperative to Ensure Uninterrupted HIV Care Following Therapeutic Trials: One Experience in Peru.
AIDS Patient Care STDS. 2022 Jun;36(6):205-207. doi: 10.1089/apc.2022.0075.
3
Potential benefits and burdens of National Institutes of Health and National Institute of Mental Health clinical trial policies.
Contemp Clin Trials. 2021 Apr;103:106328. doi: 10.1016/j.cct.2021.106328. Epub 2021 Feb 22.
4
The patient's safety and access to experimental drugs after the termination of clinical trials: regulations and trends.
Eur J Clin Pharmacol. 2018 Aug;74(8):1001-1010. doi: 10.1007/s00228-018-2474-9. Epub 2018 May 12.
6
The potential exploitation of research participants in high income countries who lack access to health care.
Br J Clin Pharmacol. 2016 May;81(5):857-64. doi: 10.1111/bcp.12879. Epub 2016 Feb 29.
7
Reciprocity-based reasons for benefiting research participants: most fail, the most plausible is problematic.
Bioethics. 2014 Nov;28(9):456-71. doi: 10.1111/bioe.12039. Epub 2013 Dec 6.
8
Ethical issues in HIV prevention research with people who inject drugs.
Clin Trials. 2014 Apr;11(2):239-45. doi: 10.1177/1740774513505157. Epub 2013 Oct 14.
9
Reasons Why Post-Trial Access to Trial Drugs Should, or Need not be Ensured to Research Participants: A Systematic Review.
Public Health Ethics. 2011 Jul;4(2):160-184. doi: 10.1093/phe/phr013. Epub 2011 Jul 11.
10
Ethical imperative of posttrial access to antiretroviral treatment.
Am J Public Health. 2010 Jun;100(6):966-7; author reply 967. doi: 10.2105/AJPH.2009.186288. Epub 2010 Apr 15.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验